Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study.
Herpes Zoster
Shingrix
Zostavax
catch-up campaign
shingles
vaccine hesitancy
vaccine uptake
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
received:
06
09
2022
revised:
16
10
2022
accepted:
20
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Herpes Zoster (shingles) is an infection that occurs when varicella-zoster virus reactivates from the latent state. Incidence and severity of Herpes Zoster disease increase with age. Antiviral drugs are the elective treatment; however, prevention of disease reactivation through effective and safe vaccines is available in Italy out-of-pocket from age 65 onwards. The Romagna Local Health Authority (northern Italy) administered catch-up vaccinations in March-May 2022 for immunizations not performed during the COVID-19 pandemic. In this study, adherence rates to the catch-up campaign and recall activities adopted in two centers were investigated. The uptakes for only the catch-up vaccinations were 11.4% and 12.4%. Having suffered from Herpes Zoster or having family members who suffered from it would not seem to be drivers of increased uptake. Although sending text-messages to all involved patients was the main motivation for vaccine uptake (85.7-95.1%), word of mouth and web/news advertising also contributed to adoption in Center No. 2. In both centers, the need for greater synergy between public health departments and general practitioners to engage their patients emerged, as did the need for additional recall measures. Studying the main drivers of vaccine hesitancy, especially at the local level, can help in targeting campaigns and catch-up activities in order to achieve widespread acceptance.
Identifiants
pubmed: 36298636
pii: vaccines10101770
doi: 10.3390/vaccines10101770
pmc: PMC9611813
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Aging Clin Exp Res. 2019 Mar;31(3):421-423
pubmed: 30737649
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):80-84
pubmed: 35051134
J Pers Med. 2022 Jan 20;12(2):
pubmed: 35207628
Vaccines (Basel). 2021 Aug 06;9(8):
pubmed: 34452000
PLoS One. 2019 Aug 1;14(8):e0220230
pubmed: 31369608
Pharmaceuticals (Basel). 2022 Mar 08;15(3):
pubmed: 35337120
Lancet Public Health. 2018 Feb;3(2):e82-e90
pubmed: 29276017
J Clin Virol. 2010 May;48 Suppl 1:S20-8
pubmed: 20510264
N Engl J Med. 2005 Jun 2;352(22):2271-84
pubmed: 15930418
JMIR Form Res. 2022 Jul 18;6(7):e33260
pubmed: 35724339
Am Fam Physician. 2002 Nov 1;66(9):1723-30
pubmed: 12449270
Vaccine. 2009 Feb 25;27(9):1454-67
pubmed: 19135492
Am J Prev Med. 2017 Mar;52(3):362-372
pubmed: 27720342
Vaccines (Basel). 2021 Oct 18;9(10):
pubmed: 34696308
Int J Environ Res Public Health. 2021 Jan 22;18(3):
pubmed: 33499422
Hum Vaccin Immunother. 2021 Nov 2;17(11):4163-4170
pubmed: 34370590
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Hum Vaccin Immunother. 2017 Feb;13(2):339-345
pubmed: 28032814
Curr Opin Pediatr. 2020 Feb;32(1):151-159
pubmed: 31790027
Epidemiol Infect. 2001 Oct;127(2):305-14
pubmed: 11693508
Clin Infect Dis. 2009 Sep 15;49(6):817-40
pubmed: 19659433
Eur J Pain. 1999 Dec;3(4):335-342
pubmed: 10700361
Vaccine. 2003 Mar 7;21(11-12):1256-67
pubmed: 12559807
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
J Adolesc Health. 2019 Jul;65(1):116-123
pubmed: 30879881
Vaccine. 2009 Jan 7;27(2):192-6
pubmed: 18996427